Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifitegrast - Bausch and Lomb

Next Previous
Drug Profile

Lifitegrast - Bausch and Lomb

Alternative Names: Lifitegrast; OJL-332; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 27 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer Bausch & Lomb; Novartis; SARcode Bioscience; Shire
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Benzofurans; Eye disorder therapies; Isoquinolines; Propionic acids; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • Discontinued Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 27 Mar 2026 Discontinued - Phase-I for Diabetic macular oedema in USA (Ophthalmic) (Bausch & Lomb Pipeline, March 2026)
  • 27 Mar 2026 Discontinued - Phase-II for Allergic conjunctivitis in USA (Ophthalmic) (Bausch & Lomb Pipeline, March 2026)
  • 27 Mar 2026 Discontinued - Preclinical for Atopic dermatitis in USA (Topical) (Bausch & Lomb Pipeline, March 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top